Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
With our partners at CellTrials.org, we’ve developed an interactive map that displays the numbers of CAR T-cell trials taking place in countries across the world. Trials are categorized as targeting either hematologic malignancies or solid tumors. Click a country on the map to access the data on trials occurring there or scroll through the list of countries using the arrows to the left or right of the country name.
With our partners at CellTrials.org, we’ve developed an interactive map that displays the numbers of CAR T-cell trials taking place in countries across the world. Trials are categorized as targeting either hematologic malignancies or solid tumors. Click a country on the map to access the data on trials occurring there or scroll through the list of countries using the arrows to the left or right of the country name.
Researchers developed the first chimeric antigen receptor T cells, modified immune cells that can recognize tough-to-target cancer antigens, about three decades ago. In the past 20 years, scientists have tweaked CAR-T cells to become potent weapons against tumors. These efforts have been rewarded with several recent approvals by the US Food and Drug Administration (FDA). Last year, the FDA approved the first CAR T-cell therapy, Kymriah, which was developed by pharmaceutical giant Novartis and uses modified patient immune cells to target a particularly recalcitrant type of acute lymphoblastic leukemia. Later in 2017, the FDA granted approval to California-based Kite Pharma, which developed Yescarta, a similar CAR T-cell therapy for patients whose large B-cell lymphoma fails to respond to two other types of cancer treatments.
A number of other companies are conducting their own trials to attain regulatory approval for their own approaches to CAR T-cell therapy, which shares attributes of cell therapy, gene therapy, and immunotherapy.
